[Advances in Immuno-Oncology 2019] Cell-Based Checkpoint Receptor Assays and Human Tumor Microenvironment Models in Immunotherapy Drug Discovery: Eurofins Discovery Portfolio of Services

[Advances in Immuno-Oncology 2019] Cell-Based Checkpoint Receptor Assays and Human Tumor Microenvironment Models in Immunotherapy Drug Discovery: Eurofins Discovery Portfolio of Services
File Name/Number:
Advances in Immuno-Oncology 2019

Year:
2019

Immunotherapies have revolutionized treatment options for cancers resistant or recalcitrant to conventional approaches. Clinical successes achieved with immuno-oncology (IO) drugs that restore a patient’s capacity to mount an anti-cancer immune response are compelling, although improved objective response rates are limited to a minority of patients (10%-30%). To improve patients’ outcomes with new therapies or enhanced combination strategies, implementation of innovative and translationally relevant target validation assays plus IO qualification services is critical early in discovery.

Using the industry-validated Enzyme Fragment Complementation technology, PathHunter® Checkpoint Assays measure compound-mediated activation and signaling from co-inhibitory and co-stimulatory checkpoint receptors. These one-day assays provide rapid and sensitive screening of biologics and small molecules with the robustness and reproducibility required for use in characterization, relative potency, and QC lot release testing of immunotherapy drugs. Data are presented for bioassays targeting PD-1 and the SIRPα/CD47 signaling axis, an emerging IO target.

BioMAP® Oncology systems recapitulate stromal or vascular immune-tumor microenvironments in human, co-culture model systems to assess impact of compounds or combinations on clinically relevant protein biomarkers. Comparisons to a proprietary reference database power predictive analytics of this translational discovery platform. Activity profile data demonstrating the ability to qualify or deprioritize candidates are presented for approved IO therapies targeting PD-1, anti-cancer drugs, and the IDO inhibitor epacadostat, as well as their combinations.

PathHunter Checkpoint Assays and BioMAP Phenotypic Profiling services are reproducible and complementary in vitro approaches to help overcome obstacles to the identification and preclinical validation of IO therapeutic targets and strategies.